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Ethical issuEs confronting 
clinical rEsEarch   
How did we get here? 






How Did We Get Here? 
• War Research 
• Drug Trials 






• 1946 AMA Code of Ethics 
– response to concerns about research abuses 
• 1947 Nuremberg Code 
– in reaction to WWII atrocities 
– 10 principles set by Nuremberg Military 
Tribunal 
• No more war crimes 
• Informed consent necessary 
Ethical codEs 
• 1964 Declaration of Helsinki 
– rules for therapeutic and non-therapeutic research 
– legal guardians can grant permission 




• 1938 FDA 
– in response to 107 human deaths attributed to a 
liquid preparation of the first sulfa drug used to 
treat certain infectious bacteria, including 
pneumonia and strep throat. 




• 1961 First investigator investigation by 
FDA 
– Found that investigator fabricated results of 25 
drug trials done for different companies on 
adults, infants, and children 
 
drug trials rEgulations 
• 1963 Certification of Informed Consent 
(FDA) 
– certification that informed consent will be 
obtained required of investigators conducting 
drug trials 
 
• 1963 Investigational Drug Regulations 
– IND application established 
– Protocol, names and qualifications of 
investigators, study sites must be submitted to 
FDA 
drug trials rEgulations 
 
• 1972 FDA monitoring by drug study 
sponsors 
• 1988 Guidelines for Monitoring Clinical 
Investigations 
– FDA requires QA audits 
 
thalidomidE trial 
• 1962 Kefauver-Harris Amendments to FDA 
– result of thalidomide trial that caused infant 
deformities when taken by pregnant women 
– Drug efficacy must be proven prior to marketing 
– Informed Consent is necessary 
– Adverse Events must be reported 
ProtEctions WomEn  
• 1975 HHS Special protections for Pregnant 
Women 
– trial must meet mother’s health needs 
– minimal risk to fetus 
 
• 1977 FDA Inclusion of Women 
– women of childbearing potential must be 
excluded from phase I and early phase II studies 
unless have a life-threatening disease  
– revised 1993 “reasonable” number included 
 
ProtEctions minors 
• 1983 HHS Special Protections for Children 
 
• 2002 Best Pharmaceuticals for Children Act 
– drugs already on the market will be carefully 
studied in children 
 
QuEstionablE Ethics 
• 1966 Beecher article 
– 22 examples of unethical or questionably 
ethical studies including Willowbrook State 
School in New York 
• retarded children are made to ingest hepatitis virus 
 
• 1966 AMA adopts ethical guidelines for 
clinical investigations 
rEgulatory rEsPonsE 
• 1966 HHS policy of independent review 
– HHS funded research must have an 
independent review made by “institutional 
associates” that includes methodology and 
informed consent  
 




• 1967 FDA creates division of Scientific 
Investigation 
– prison based research 
– IND/IDE research 
– suspect list 
• 1967 FDA permits oral consent 
• 1971 FDA requires IRB review 
– for studies on institutionalized subjects 
 
tuskEgEE 
• 1972 Details of Tuskegee emerge 
• 1972 OPRR established within NIH 
– to protect participants  
– becomes OHRP in 1999 
• 1974 National Research Act 
– establishes National Commission for the 
Protection of Human Subjects in Biomedical & 
Behavioral Research  
– in reaction to Tuskegee 
Ethical & fEdEral codEs 
• 1974 HHS requires informed consent for all 
federally funded studies 
• 1975 Declaration of Helsinki signed by 34 
nations 
– treatment of participants in biomedical research 
– PI responsible for trial conduct 
• 1976 FDA Expands Bioresearch Monitoring 
– 1977 Bioresearch Monitoring Program 
from thE doh 
• 1978 Protections for Prisoners 
– prisoner advocate must review research 
– OPRR approval necessary 
– risks can be no greater than for non prisoners 
– no special advantages to prisoners 
 
• 1979 Belmont Report 




• 1981 President’s Commission for the Study of 
Ethical Problems in Medicine and Biomedical 
and Behavioral Research 
– recommends uniform federal regulatory system 
 
• 1990 International Conference on 
Harmonization (ICH) 
– Europe, Japan, and US create guidelines for drug 
trials across borders 
 
• 1991 Common Rule (45 CFR 46) -  now 18 
Do the Federal and Ethical Codes 
governing research assist the PI 
in these Scenarios? 
SCENERIO 1 
• A PI is performing a clinical trial of a new 
drug.  Preliminary data shows that the drug 
appears to be failing to provide any benefit 
and has some unexpected side effects. 
– Should the trial be continued? 
– Should the unexpected side effects be reported 
as SAEs? 
– Should participants be informed of this 
preliminary information? 
• Should the trial be continued? 
– depends on data and adverse events 
– quite often early results show no benefits  
 
• Should the unexpected side effects be 




• Should participants be informed of this 
preliminary information? 
– Any adverse event that would cause a 
participant to reconsider study participation 
should be reported to the participant in the 
form of a consent addendum. 
 
SCENERIO 2 
• The researcher’s retired father owns stock in 
the drug company.  The company asks the 
researcher to delay reporting the results until 
after the company’s annual meeting in 2 
months because of a concern about a drop in 
the stock price. 
– Should the trial be stopped? 
– Is there a financial conflict of interest? 
– Should the PI withhold reporting results? 
• How could this affect participants? 
• Should the trial be stopped? 
– The drug company wants to withhold information. 
There may a real problem with this trial. 
 
• Should the PI withhold reporting results? 
– How could this affect participants? 
• Withholding information could cause real harm to 
the participants. 
 
• Is there a financial conflict of interest? 
– If the aggregate amount of the stock is $10,000 or 
more. 
• Participants should be aware of COI. 
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